Major Strides in HER2 Blockade for Metastatic Breast Cancer

被引：10
作者：
Sharma, Priyanka [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Internal Med, Kansas City, KS 66103 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 07期
关键词：
TRASTUZUMAB; PERTUZUMAB; DOCETAXEL; SURVIVAL;
D O I：
10.1056/NEJMe1916310
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Breast cancer that is characterized by amplification or overexpression of human epidermal growth factor receptor 2 (HER2) accounts for 15 to 20% of all forms of the disease. The advent of HER2-targeted drugs, such as trastuzumab, pertuzumab, lapatinib, and the antibody-drug conjugate trastuzumab emtansine, has revolutionized the treatment of both early-stage and metastatic HER2-positive breast cancer.(1-4) The increasing availability of HER2-targeted agents has led to improved outcomes for patients with HER2-positive metastatic breast cancer, as reported in a study in which overall survival rose from a median of 38.7 months to 51.1 months from 2008 through 2012.(5) The standard first-line . . .
引用
收藏
页码：669 / 671
页数：3
相关论文
共 50 条
  • [1] Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity
    Ajgal, Z.
    de Percin, S.
    Dieras, V.
    Pierga, J. Y.
    Campana, F.
    Fourquet, A.
    Kirova, Y. M.
    CANCER RADIOTHERAPIE, 2017, 21 (02): : 114 - 118
  • [2] HER2 overexpression in metastatic breast cancer: development of therapies
    Pivot, X.
    Jary, M.
    Dobi, E.
    Bazan, F.
    Chaigneau, L.
    Cals, L.
    Almotlak, H.
    Montcuquet, P.
    Meneveau, N.
    Villanueva, C.
    ONCOLOGIE, 2012, 14 (01) : 37 - 40
  • [3] Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
    Bon, Giulia
    Pizzuti, Laura
    Laquintana, Valentina
    Loria, Rossella
    Porru, Manuela
    Marchio, Caterina
    Krasniqi, Eriseld
    Barba, Maddalena
    Maugeri-Sacca, Marcello
    Gamucci, Teresa
    Berardi, Rossana
    Livi, Lorenzo
    Ficorella, Corrado
    Natoli, Clara
    Cortesi, Enrico
    Generali, Daniele
    La Verde, Nicla
    Cassano, Alessandra
    Bria, Emilio
    Moscetti, Luca
    Michelotti, Andrea
    Adamo, Vincenzo
    Zamagni, Claudio
    Tonini, Giuseppe
    Barchiesi, Giacomo
    Mazzotta, Marco
    Marinelli, Daniele
    Tomao, Silverio
    Marchetti, Paolo
    Valerio, Maria Rosaria
    Mirabelli, Rosanna
    Russo, Antonio
    Fabbri, Maria Agnese
    D'Ostilio, Nicola
    Veltri, Enzo
    Corsi, Domenico
    Garrone, Ornella
    Paris, Ida
    Sarobba, Giuseppina
    Giotta, Francesco
    Garufi, Carlo
    Cazzaniga, Marina
    Del Medico, Pietro
    Roselli, Mario
    Sanguineti, Giuseppe
    Sperduti, Isabella
    Sapino, Anna
    De Maria, Ruggero
    Leonetti, Carlo
    Di Leo, Angelo
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [4] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [5] Sparing chemotherapy with dual HER2 blockade in combination with endocrine therapy for advanced HER2 positive breast cancer
    Werutsky, Gustavo
    Reinert, Tomas
    Fay, Andre Poisl
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S573 - S576
  • [6] Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity
    Ben Dhia, S.
    Loap, P.
    Loirat, D.
    Vincent-Salomon, A.
    Cao, K.
    Escalup, L.
    Fourquet, A.
    Kirova, Y.
    CANCER RADIOTHERAPIE, 2021, 25 (05): : 424 - 431
  • [7] Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
    Van Raemdonck, Elisa
    Floris, G.
    Berteloot, P.
    Laenen, A.
    Vergote, I.
    Wildiers, H.
    Punie, K.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 183 - 194
  • [8] Somatic mutations of the HER2 in metastatic breast cancer
    Fang, Yi
    Jiang, Yanxia
    Wang, Xin
    Yang, Xue
    Gao, Yinqi
    Wang, Jing
    TUMOR BIOLOGY, 2014, 35 (12) : 11851 - 11854
  • [9] Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
    Moilanen, Tiina
    Mustanoja, Susanna
    Karihtala, Peeter
    Koivunen, Jussi P.
    ESMO OPEN, 2017, 2 (03)
  • [10] Cardiac toxicity in breast cancer patients treated with dual HER2 blockade
    Valachis, Antonis
    Nearchou, Andreas
    Polyzos, Nikolaos P.
    Lind, Pehr
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (09) : 2245 - 2252
12345